Regulatory Filings • Mar 12, 2014
Regulatory Filings
Open in ViewerOpens in native device viewer
This document comprises a pricing statement relating to the Offer described in the prospectus published by Pets at Home Group Plc (the "Company") on 28 February 2014 (the "Prospectus") prepared in accordance with the prospectus rules (the "Prospectus Rules") of the Financial Conduct Authority (the "FCA") made under section 73A of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). This document must be read in conjunction with the Prospectus. Capitalised terms used in this document and not defined herein have the same meaning as given to them in the Prospectus. This document is an advertisement for the purposes of Rule 3.3.2R of the Prospectus Rules and does not constitute a prospectus. Investors should not subscribe for or purchase any Shares on the basis of this document alone and should refer to information in the Prospectus, in particular the section entitled "Risk Factors" set out in Part II of the Prospectus. Copies of the Prospectus and this document are available on the Company's website at http://investors.petsathome.com.
Application will be made to the FCA in its capacity as competent authority under the FSMA for all of the Shares of the Company, issued and to be issued in connection with the Offer to be admitted to the premium listing segment of the Official List maintained by the FCA (the "Official List") and to the London Stock Exchange plc (the "London Stock Exchange") for such Shares to be admitted to trading on the London Stock Exchange's main market for listed securities (together, "Admission"). Admission to trading on the London Stock Exchange's main market for listed securities constitutes admission to trading on a regulated market. Conditional dealings in the Shares are expected to commence on the London Stock Exchange at 8.00 a.m. on 12 March 2014. It is expected that Admission will become effective, and that unconditional dealings will commence on the London Stock Exchange, at 8.00 a.m. on 17 March 2014. All dealings in Shares prior to the commencement of unconditional dealings will be on a "when issued" basis and of no effect if Admission does not take place and will be at the sole risk of the parties concerned. Investors should note that only investors who applied for, and were allocated Shares in the Institutional Offer or the Intermediaries Offer will be able to deal in Shares on a conditional basis. Eligible Colleagues who have been allocated Shares pursuant to the terms of the Colleague Offer will not be able to deal in Shares on a conditional basis prior to Admission. No application has been, or is currently intended to be, made for the Shares to be admitted to listing or trading on any other stock exchange.
(incorporated under the Companies Act 2006 and registered in England and Wales with registered number 8885072)
Offer of 200,000,000 Shares at an Offer Price of £2.45 per Share and admission to the premium listing segment of the Official List and to trading on the main market of the London Stock Exchange
Sponsor
Joint Global Coordinators and Joint Bookrunners
BofA Merrill Lynch Goldman Sachs International KKR
Co-Lead Manager
Nomura
This document does not constitute or form part of any offer to sell or issue, or any invitation or solicitation of any offer to invest in or purchase, any Shares to any person in any jurisdiction where it is unlawful to make such offer or solicitation and is not for distribution in or into the United States, Canada, Australia or Japan. Any failure to observe these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Shares have not been, and will not be, registered under the US Securities Act of 1933 (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States or under the applicable securities laws of Canada, Australia or Japan. Subject to certain exceptions, the Shares may not be offered or sold in the United States, Canada, Australia or Japan or to, or for the account or benefit of, any national, resident or citizen of the United States, Canada, Australia or Japan. Merrill Lynch International ("BofA Merrill Lynch"), Goldman Sachs International ("Goldman Sachs"), KKR Capital Markets Limited ("KKR Capital Markets") and Nomura International plc ("Nomura") may arrange for the offer and sale of the Shares in the United States only to persons reasonably believed to be qualified institutional buyers ("QIBs") as defined in Rule 144A under the Securities Act ("Rule 144A"), either in reliance on Rule 144A or pursuant to another exemption from or in a transaction not subject to the registration requirements of the Securities Act. The Shares are being offered and sold outside the United States in reliance on Regulation S under the Securities Act ("Regulation S"). There will be no public offer of the Shares in the United States. Prospective investors are hereby notified that the sellers of the Shares may be relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A of the Securities Act.
BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets and Nomura, each of which, in the United Kingdom, is authorised by the Prudential Regulation Authority ("PRA") and regulated by the PRA and the FCA, are acting exclusively for the Company and no one else in connection with the Offer, and will not regard any other person (whether or not a recipient of this document or the Prospectus) as their respective clients in relation to the Offer and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for giving advice in relation to the Offer, the contents of this document, the Prospectus or any transaction or arrangement referred to therein.
The distribution of this document and the offer of the Shares contemplated by the Prospectus in certain jurisdictions may be restricted by law. No action has been or will be taken by the Company, the Directors, BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura, the Principal Shareholder or the Selling Shareholder or any such person's affiliates to permit a public offering of the Shares or to permit the possession or distribution of this document or the Prospectus (or any other offering or publicity materials relating to the Shares) in any jurisdiction other than the United Kingdom, where action for that purpose may be required. Accordingly, none of this document, the Prospectus, any advertisement or any other offering material may be distributed or published in any jurisdiction except under the circumstances that will result in compliance with any applicable laws and regulations. Persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Any failure to comply with these restrictions and requirements may constitute a violation of the securities laws of any such jurisdiction.
In particular, no actions have been taken to allow for a public offering of the Shares under the applicable securities laws of any jurisdiction (other than the United Kingdom), including Australia, Canada, Japan or the United States.
Without prejudice to the Company's legal or regulatory obligations to publish a supplementary prospectus, neither the delivery of this document nor Admission shall, under any circumstances, create any implication that there has been no change in the affairs of the Group since the date hereof or that the information is correct as of any time subsequent to the date hereof.
The contents of this document should not be construed as legal, financial or tax advice. Each prospective investor should consult his, her or its own legal, financial or tax adviser for legal, financial or tax advice in relation to an investment in Shares.
The Shares referred to in this document and offered by the Prospectus have not been approved or disapproved by the United States Securities and Exchange Commission, any state securities commission in the United States or any other United States regulatory authority, nor have any such authorities passed upon, or endorsed the merits of, the Offer or the accuracy of this document or the Prospectus. Any representation to the contrary is a criminal offence in the United States.
Until 40 days after the commencement of the Offer, an offer or sale of Shares within the United States by any dealer (whether or not participating in the Offer) may violate the registration requirements of the Securities Act if such offer or sale is made otherwise than in accordance with Rule 144A of the Securities Act.
In connection with the Offer, any of BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura and any of their affiliates, acting as investors for their own accounts, may invest in the Shares, and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for its own accounts in such Shares and other securities of the Company or related investments in connection with the Offer or otherwise. Accordingly, references in this document or the Prospectus to the Shares being issued, offered, subscribed for, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, any of BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura and any of its affiliates acting as an investor for its own accounts. Neither BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura nor any of their affiliates intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so. In addition, certain of BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura or their affiliates may enter into financing arrangements (including swaps) with investors in connection with which BofA Merrill Lynch, Goldman Sachs, KKR Capital Markets, Nomura (or their affiliates) may from time to time acquire, hold or dispose of Shares.
This document and the Prospectus have been prepared on the basis that all offers of Shares, other than the United Kingdom, will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area ("EEA"), from the requirement to produce a prospectus for offers of shares. Accordingly, any person making or intending to make any offer within the EEA of Shares which are comprised in the Offer contemplated in the Prospectus should only do so in circumstances in which no obligation arises for the Company, the Selling Shareholder or any of the Underwriters to produce a prospectus for such offer. None of the Company, the Principal Shareholder, the Selling Shareholder and the Underwriters have authorised, nor will they authorise, the making of any offer of Shares through any financial intermediary (other than in connection with the Intermediaries Offer), other than offers made by Underwriters which constitute the final placement of Shares contemplated in the Prospectus.
NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN APPLICATION FOR A LICENCE HAS BEEN FILED UNDER RSA 421-B OF THE NEW HAMPSHIRE REVISED STATUTES ("RSA 421-B") WITH THE STATE OF NEW HAMPSHIRE NOR THE FACT THAT A SECURITY IS EFFECTIVELY REGISTERED OR A PERSON IS LICENSED IN THE STATE OF NEW HAMPSHIRE CONSTITUTES A FINDING BY THE SECRETARY OF STATE OF THE STATE OF NEW HAMPSHIRE THAT ANY DOCUMENT FILED UNDER RSA 421-B IS TRUE, COMPLETE AND NOT MISLEADING. NEITHER ANY SUCH FACT NOR THE FACT THAT AN EXEMPTION OR EXCEPTION IS AVAILABLE FOR A SECURITY OR A TRANSACTION MEANS THAT THE SECRETARY OF STATE OF THE STATE OF NEW HAMPSHIRE HAS PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS OF, OR RECOMMENDED OR GIVEN APPROVAL TO, ANY PERSON, SECURITY OR TRANSACTION. IT IS UNLAWFUL TO MAKE, OR CAUSE TO BE MADE, TO ANY PROSPECTIVE INVESTOR, CUSTOMER, OR CLIENT ANY REPRESENTATION INCONSISTENT WITH THE PROVISIONS OF THIS PARAGRAPH.
The Company has agreed that, for so long as any of the Shares are "Restricted Securities" as defined in Rule 144(a)(3) under the Securities Act, the Company will, during any period in which it is neither subject to section 13 or 15(d) of the Exchange Act, nor exempt from reporting under the Exchange Act pursuant to Rule 12g3-2(b) thereunder, make available to any holder or beneficial owner of such restricted securities or to any prospective investor in such restricted securities designated by such holder or beneficial owner, upon the request of such holder, beneficial owner or prospective investor, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. The Company expects that it will be exempt from reporting under the Exchange Act pursuant to Rule 12g3-2(b) thereunder.
Certain statements contained in this document and the Prospectus constitute "forward-looking statements". In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "continues", "estimates", "plans", "prepares", "anticipates", "expects", "intends", "aims", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. Investors should specifically consider the factors identified in this document and the Prospectus which could cause actual results to differ before making an investment decision. Undue reliance should not be placed on any forward-looking statements as such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company and/or the Group, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Undue reliance should not be placed on any forwardlooking statements as such forward-looking statements are based on numerous assumptions regarding the Company's, and/or the Group's present and future business strategies and the environment in which the Company and/or the Group will operate in the future. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in the global political, economic and/or business sphere, competitive, market and regulatory forces, future exchange and interest rates, changes in tax rates and future business combinations or dispositions. Such risks, uncertainties and other factors are set out more fully in Part II (Risk Factors) of the Prospectus and include, among others: risks relating to the Group's business, risks relating to the industry, risks relating to the Group's operations in certain jurisdictions and risks relating to the Group's financial structure. Any forward-looking statements in this document or the Prospectus speak only as at the date of publication of this document and the Prospectus respectively. Except as required by the FCA, the London Stock Exchange or applicable law (including as may be required by the Prospectus Rules, Listing Rules and the Disclosure and Transparency Rules), the Company, the Directors and the Underwriters expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forwardlooking statements contained in this document or the Prospectus to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
In connection with the Offer, Merrill Lynch International (as Stabilising Manager), or any of its agents, may (but will be under no obligation to), to the extent permitted by applicable law and for stabilisation purposes, over-allot Shares up to a total of 15% of the total number of Shares comprised in the Offer or effect other transactions with a view to supporting the market price of the Shares at a higher level than that which might otherwise prevail in the open market. The Stabilising Manager is not required to enter into such transactions and such transactions may be effected on any securities market, over-the-counter market, stock exchange or otherwise and may be undertaken at any time during the period commencing on the date of the conditional dealings in the Shares on the London Stock Exchange and ending no later than 30 calendar days thereafter. Such stabilisation, if commenced, may be discontinued at any time without prior notice. However, there will be no obligation on the Stabilising Manager or any of its agents to effect stabilising transactions and there is no assurance that stabilising transactions will be undertaken. In no event will measures be taken to stabilise the market price of the Shares above the Offer Price. Except as required by law or regulation, neither the Stabilising Manager nor any of its agents intends to disclose the extent of any over-allotments made and/or stabilisation transactions conducted in relation to the Offer.
For the purposes of allowing the Stabilising Manager to cover short positions resulting from any such overallotment and/or from sales of Shares effected by it during the stabilising period, it has entered into the Overallotment Option with the Over-allotment Shareholders pursuant to which it may purchase, or procure purchasers for Over-allotment Shares (representing up to 15% of the total number of Shares comprised in the Offer and before any utilisation of the Over-allotment Arrangements) at the Offer Price. The Over-allotment Option may be exercised in whole or in part upon notice by the Stabilising Manager at any time on or before the 30th calendar day after the commencement of conditional dealings in the Shares on the London Stock Exchange. Any Overallotment Shares made available pursuant to the Over-allotment Option will be subscribed for on the same terms and conditions as Shares being offered pursuant to the Offer and will rank pari passu in all respects with, and form a single class with, all other Shares (including for all dividends and other distributions declared, made or paid on the Shares).
The contents of the Group's Website or any website directly or indirectly linked to this Website have not been verified and do not form any part of this document or the Prospectus, and investors should not rely on such information.
In addition to those documents set out in Section 24 (Documents for Inspection) of Part XVIII (Additional Information) of the Prospectus, copies of this document will be available for inspection during usual business hours on any weekday (Saturdays, Sundays and public holidays excepted) at the offices of Simpson Thacher & Bartlett LLP, CityPoint, One Ropemaker Street, London EC2Y 9HU until 11 April, 2014.
This document is dated 12 March 2014.
Each of the following times and dates are indicative only and subject to change without further notice. References to a time of day are to London time.
| Time and Date | |
|---|---|
| Announcement of the Offer Price and Offer Size, publication of this Pricing Statement and notification of allocations of Shares |
12 March 2014 |
| Commencement of conditional dealings in Shares on the London Stock Exchange (1) (2) | 8.00 a.m. on 12 March 2014 |
| Admission and commencement of unconditional dealings in Shares on the London Stock Exchange |
8.00 a.m. on 17 March 2014 |
| Shares credited to CREST accounts (where applicable) (3) | 8.00 a.m. on 17 March 2014 |
| Despatch of definitive share certificates (where applicable) (3) | Week commencing 31 March 2014 |
| Stabilisation End Date | 11 April 2014 |
| Price (per Share) . |
£2.45 |
|---|---|
| Number of Shares in issue on Admission (1) | 500,000,000 |
| Number of Shares comprised in the Offer (2) | 200,000,000 |
| - of which New Shares to be issued to facilitate the repayment of outstanding amounts owing under the Existing Senior Facilities Agreement and pay the estimated fees and expenses of the Offer (3) |
114,187,755 |
| - of which New Shares to be issued to repay Shareholder Debt (4) | 75,273,191 |
| - of which Existing Shares(2) | 10,539,054 |
| Number of Shares in the Offer as a percentage of total number of Shares in existence on Admission (5) | 40.0% |
| Dilution of Existing Shareholders following Admission (6) | 37.9% |
| Number of Shares subject to the Over-allotment Option (7) | 30,000,000 |
| Net proceeds of the Offer receivable by the Company to be used to facilitate the repayment of outstanding amounts owing under the Existing Senior Facilities Agreement (8) |
£240 million |
| Net proceeds of the Offer receivable by the Company to be used to repay Shareholder Debt (4) | £184 million |
| Gross proceeds of the Offer receivable by the Selling Shareholder(9) . |
£26 million |
| Market capitalisation of the Company at the Offer Price (10) | £1,225 million |
The beneficial interests of the Directors and the Senior Executives in the share capital of the Company on Admission and immediately following Admission are as set out in the table below.
| Director/Senior Executive | Number of Shares on Admission (1) (2) |
Percentage of issued Shares on Admission (1) (2) |
Number of Shares to be sold pursuant to the Offer (1) (3) |
Percentage of Shares to be sold pursuant to the Offer (1) (3) |
Number of Shares immediately following Admission (1) (4) |
Percentage of issued Shares immediately following Admission (1) (4) |
|---|---|---|---|---|---|---|
| Tony DeNunzio (5) |
3,977,342 | 0.8% | 819,316 | 20.6% | 3,158,026 | 0.6% |
| Dennis Millard (6) | 16,327 | 0.0% | 0 | 0.0% | 16,327 | 0.0% |
| Nick Wood (7) (8) | 7,340,760 | 1.5% | 1,835,189 | 25.0% | 5,505,571 | 1.1% |
| Ian Kellett (5) (7) | 4,640,415 | 0.9% | 593,359 | 12.8% | 4,047,056 | 0.8% |
| Brian Carroll (6) (9) | 40,816 | 0.0% | 0 | 0.0% | 40,816 | 0.0% |
| Paul Coby (6) | 4,082 | 0.0% | 0 | 0.0% | 4,082 | 0.0% |
| Tessa Green (6) | 40,816 | 0.0% | 0 | 0.0% | 40,816 | 0.0% |
| Amy Stirling (6) | 16,327 | 0.0% | 0 | 0.0% | 16,327 | 0.0% |
| Sally Hopson (5) (7) | 4,315,778 | 0.9% | 970,874 | 22.5% | 3,344,904 | 0.7% |
| Peter Pritchard (7) | 4,239,289 | 0.8% | 1,059,822 | 25.0% | 3,179,467 | 0.6% |
| Phil Hackney (7) | 2,752,785 | 0.6% | 688,196 | 25.0% | 2,064,589 | 0.4% |
Notes:
(1) Following completion of the Pre-IPO Reorganisation described in Section 4 (Group Structure and IPO Reorganisation) of Part XVIII (Additional Information) of the Prospectus.
(2) Prior to the completion of the Offer.
(3) MEP Nominee Limited will sell such Shares on behalf of each relevant Director and Senior Executive.
(4) Computershare Company Nominees Limited will hold legal title to such Shares (other than in respect of Shares to be held by IPS (2008) SIPP–IM Kellett, a SIPP established by Ian Kellett) on behalf of each Director and Senior Executive.
(9) Brian Carroll has been appointed as a Non-Executive Director of the Company by the Principal Shareholder in accordance with the terms of the Relationship Agreement.
The table below sets out the Matching Awards under the CIP which will be made to the Executive Directors and the Senior Executives conditional upon and with effect from Admission.
| Executive Director/Senior Executive | Number of Shares over which Matching Awards have been made with effect from Admission (1) |
|---|---|
| Nick Wood | 433,673 |
| Ian Kellett | 326,530 |
| Sally Hopson | 306,122 |
| Peter Pritchard | 357,142 |
| Phil Hackney | 244,897 |
Notes:
(1) Assuming their vesting in full, the aggregate total of the Matching Awards to be awarded to the Executive Directors and Senior Executives on Admission will represent 0.3% of the issued Shares following Admission.
(2) Additional Matching Awards in respect of a further 785,195 Shares will be made to certain other Colleagues conditional upon and with effect from Admission which will, assuming their vesting in full, represent 0.2% of the issued Shares following Admission.
On Admission, awards under the PSP will be made to selected Colleagues (but not including the Executive Directors or the Senior Executives) over 304,455 Shares representing 0.1% of the issued Shares following Admission (assuming their vesting in full).
Insofar as is known to the Company, as at the date of this document, the persons set out in the table below are expected to have notifiable interests in 3% or more (being the threshold for notification of interests that applies to the Company and Shareholders as of Admission pursuant to Chapter 5 of the Disclosure and Transparency Rules) of the issued share capital of the Company on Admission and immediately following Admission.
| On Admission | Immediately following Admission | ||||
|---|---|---|---|---|---|
| Shareholder | Number of Shares (1) | Percentage of issued share capital (1) |
Number of Shares (1) (2) | Percentage of issued share capital (1) (2) |
|
| KKR My Best Friend Limited (3) | 186,616,538 | 37.3% | 186,616,538 | 37.3% | |
| MBF Co-Invest L.P. (3) |
44,396,548 | 8.9% | 44,396,548 | 8.9% | |
| MEP Nominee Limited (4) (5) | 40,110,102 | 8.0% | 29,980,734 | 6.0% |
(1) Following completion of the Pre-IPO Reorganisation described in Section 4 (Group Structure and IPO Reorganisation) of Part XVIII (Additional Information) of the Prospectus.
As such, notes (2), (5) and (6) of the unaudited pro forma statement of net assets as at 2 January 2014 set out in Part XIV (Unaudited Pro Forma Financial Information) of the Prospectus are updated as follows:
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.